AMSTERDAM, Sept 3 (Reuters) – French riders in the Tour de
France live an average of six years longer than the general
population and die less often of cardiovascular problems,
researchers said, which may help ease worries about the effect
of extreme exercise on the heart.
The research also offered limited assurance that doping was
unlikely to pose a major heart health risk, at least in the
short term, since any major adverse impact would have skewed the
results. Illicit use of the blood-boosting drug EPO, or
erythropoietin, has been rampant in competitive cycling since
AMSTERDAM (Reuters) – The hunt for new heart drugs is losing momentum as resources are switched to other areas, notably cancer research, where investors get a better bang for their buck.
Cardiologists fear the fight against heart disease could stall as a result, following major advances in recent decades marked by the advent of drugs to fight cholesterol, lower blood pressure and prevent dangerous blood clots.
AMSTERDAM (Reuters) – An experimental heart failure drug from Amgen and Cytokinetics missed its goal of improving shortness of breath in a mid-stage clinical trial, leaving its future uncertain.
Despite the setback in the 613-patient trial using an intravenous formulation of the medicine omecamtiv mecarbil in hospitals, Amgen said it would continue testing an oral version of the drug in a separate Phase II study.
AMSTERDAM (Reuters) – An experimental drug from Novartis to treat heart failure proved equally effective regardless of the age of patients or whether they had other medical problems, clinical trial results presented on Monday showed.
The drug, serelaxin, which is a form of a human hormone that relaxes blood vessels and eases stress on the heart and other organs, is viewed as an important medicine in the Swiss drugmaker’s developmental pipeline.
AMSTERDAM (Reuters) – Diabetes pills known as DPP-4 therapies got a mixed safety report on Monday as studies showed they did not raise the risk of heart attacks but might be linked to heart failure, where the heart fails to pump blood adequately.
Reassuringly, the medicines were not associated with increased rates of either inflammation of the pancreas or cancer – something that has been a worry in the past.